pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in greecepharmacoeconomic分析paliperidone棕榈酸酯治疗精神分裂症在希腊.pdfVIP

下载本文档

2
0
约5.75万字
约 8页
2017-09-11 发布于上海
举报
版权申诉

pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in greecepharmacoeconomic分析paliperidone棕榈酸酯治疗精神分裂症在希腊.pdf

1、本文档共8页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in greecepharmacoeconomic分析paliperidone棕榈酸酯治疗精神分裂症在希腊

Einarson et al. Annals of General Psychiatry 2012, 11:18 /content/11/1/18 PRIMARY RESEARCH Open Access Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece 1* 2 3 4 5 Thomas R Einarson , Maria Geitona , Alexandros Chaidemenos , Vasiliki Karpouza , Theodoros Mougiakos , 6 7,8 9 10 10 Periklis Paterakis , Dimitrios Ploumpidis , Dionyssios Potamitis-Komis , Roman Zilbershtein , Colin Vicente , Charles Piwko10, Panagiotis Kakkavas11, Konstantina Paparouni12, Rasmus C D Jensen13 and Michiel E H Hemels13 Abstract Background: Patients having chronic schizophrenia with frequent relapses and hospitalizations represent a great challenge, both clinically and financially. Risperidone long-acting injection (RIS-LAI) has been the main LAI atypical antipsychotic treatment in Greece. Paliperidone palmitate (PP-LAI) has recently been approved. It is dosed monthly, as opposed to biweekly for RIS-LAI, but such advantages have not yet been analysed in terms of economic evaluation. Purpose: To compare costs and outcomes of PP-LAI versus RIS-LAI in Greece. Methods: A cost-utility analysis was performed using a previously validated decision tree to model clinical pathways and costs over 1 year for stable patients started on either medication. Rates were taken from the literature. A local expert panel provided feedback on treatment patterns. All direct costs incurred by the national healthcare system were obtained from the literature and standard price lists; all were inflated to 2011 costs. Patient outcomes analyzed include